Maintenance treatment using rTMS for depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of maintenance repetitive transcranial magnetic stimulation (rTMS) in individuals with treatment-resistant depression (TRD) who have previously responded to an acute rTMS treatment. It is a double-blind, three-arm trial involving 75 participants across three sites: University of California San Diego, Weill Cornell Medicine, and Australian National University. Participants will be randomized to receive either standard maintenance rTMS, clustered maintenance rTMS, or sham maintenance rTMS over a period of six months, with the primary aim of assessing the efficacy of these treatments in sustaining brain connectivity related to mood regulation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. They met criteria for a DSM-5 diagnosis of a Major Depressive Episode (MDE) during the index episode of depression for which they have received an acute rTMS treatment course.
2. Meet criteria for either response or remission from their initial depressive illness. The MINI assessment timeline will be adjusted to allow scoring of illness symptoms prior to rTMS response. Response to acute course of treatment is defined as either a MADRS score of \<10, or a MADRS score of 10-19, plus evidence of having met response criteria on either the MADRS or another structured depression rating scale. The response is defined as a \>50% reduction in the total score from the start to the end of treatment.
3. Their initial rTMS treatment course must have consisted of at least 15 rTMS treatment sessions.
4. People between the ages of 18 and 80 at the time of screening. A written statement from the referring physician will be required to confirm that the participant demonstrates the capacity to consent.
5. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during TMS-EEG assessments and iTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
6. In good general health, as evidenced by medical history.
7. Agreement to adhere to Lifestyle Considerations throughout study duration.
8. If a person of child-bearing potential is: must take a pregnancy test at the screening visit, with results confirmed as negative by study staff

Exclusion Criteria:

* 1\. Pregnancy 2. History of or current psychotic disorder or depression with psychotic features 3. Severe borderline personality disorder based on clinical assessment. 4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder 5. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal 6. Clinically significant suicidal ideation with plan 7. Any history of ECT (greater than 8 sessions) without a clinical meaningful response in the current episode.

  8\. Recent (during the current depressive episode) or concurrent use of rapid-acting antidepressant agent (i.e., ketamine or a course of ECT) in the last 30 days 9. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma 10. Untreated or insufficiently treated endocrine disorder. 11. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) 12. Treatment with an investigational drug or other intervention within the study period 13. The patient experiences a relapse between baseline and screening, defined as a moderate depression (MADRS \>=20) and a 25% increase from screening to baseline 14. Require a benzodiazepine with a dose \> lorazepam 2 mg/day or equivalent or any anticonvulsant (with the exception of Gabapentin, pregabalin, and lamotrigine).

Where it's running

• University of California, San Diego
  San Diego, California, United States Recruiting
• Weill Cornell Medicine
  New York, New York, United States Recruiting
• Australian National University
  Canberra, Australian Capital Territory, Australia Recruiting

Study contacts

• Study coordinator: Interventional Psychiatry
• Email: iptrials@health.ucsd.edu
• Phone: 858-657-6152

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mindfulness‑augmented brain stimulation for treatment‑resistant depression

  This trial will test whether combining fast brain stimulation (iTBS) with a digital mindfulness program helps people with treatment‑resistant depression reduce symptoms and improve thinking.

  Recruiting Phase 2 University of California, San Diego · San Diego, California · NCT07512284

• Adding ketamine to ECT for treatment-resistant depression

  This trial will test whether giving IV ketamine during ECT helps adults with treatment-resistant major depression get better faster and have fewer thinking problems.

  Recruiting Phase 3 Università Vita-Salute San Raffaele · Milan · NCT07088380

• Identifying brain biomarkers for treatment-resistant major depression using deep brain stimulation

  This study is testing if deep brain stimulation can help people with severe depression who haven't found relief from regular treatments by looking for brain signals that could predict their mood changes.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT06542094

• Using gamma oscillations to predict ketamine therapy outcomes in depression

  This study is testing if brain activity measured during ketamine treatment can help predict how well it will work for people with depression that hasn't responded to other treatments.

  Recruiting at 2 sites Phase 1 Texas A&M University · Houston, Texas and 1 other locations · NCT06480201

• Understanding the impact of mood disorders and treatment responses

  This study is trying to learn more about how people with depression and bipolar disorder respond to treatment by talking to them weekly for up to 12 weeks to improve future care and predict how well medications might work.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06462196

• Individualized physical activity program for treatment-resistant depression

  This study is testing a personalized exercise program to see if it can help adults with treatment-resistant depression feel better when combined with their usual treatment.

  Recruiting Unity Health Toronto · Toronto, Ontario · NCT06404320

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.